• Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • About
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Advertise
PharmaLive
  • Marketing & Advertising
  • R&D
  • Therapeutics
  • Resources
  • Manny Awards
  • Events
  • Issue Archives
  • Subscribe
  • Search
  • Menu

Alnylam scores another FDA nod in hATTR

Therapeutics

Alnylam scores another FDA nod in hATTR

Published: Jun 14, 2022

By Mark Terry

BioSpace

Almost a month ahead of schedule, the U.S. Food and Drug Administration has approved Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults.

This early decision came as a surprise for many, as the FDA had originally extended the review period from April to July 14.

The disease is rare, inherited, quickly progressive and fatal, with few treatment options. Polyneuropathy is a malfunction of many peripheral nerves throughout the body, and hATTR is caused by mutations in the TTR gene. The TTR protein is mostly produced in the liver and normally carries vitamin A.

Alnylam CEO Yvonne Greenstreet

The approval was based on positive nine-month data from the Phase III HELIOS-A trial. In it, Amvuttra improved the signs and symptoms of polyneuropathy. More than 50% of patients receiving the drug had their symptoms stopped or reversed.

Alnylam evaluated the efficacy of the drug by comparing the Amvuttra group in HELIOS-A with the placebo group from the Phase III APOLLO trial of patisiran. This was a randomized, controlled trial in a comparable patient population. Patisiran, under the brand name Onpattro, is Alnylam’s approved drug for polyneuropathy of hATTR.

“Twenty years ago, Alnylam was founded with the bold vision for RNA interference to make a meaningful impact on the lives of people around the world in need of new approaches to address serious diseases with significant unmet medical needs, such as hATTR amyloidosis,” Yvonne Greenstreet, CEO of Alnylam, said in a statement. “Today, Amvuttra has the potential to change the standard of care for people living with the polyneuropathy of this devastating disease.”

The drug is an RNA interference (RNAi) therapeutic. It is made up of a double-stranded small interfering RNA (siRNA) that targets mutant and wild-type transthyretin (TTR) messenger RNA (mRNA). Essentially, it suppresses the expression of a specific gene or gene segment, preventing the production of an abnormal protein. Vutrisiran for polyneuropathy is dosed via subcutaneous injection once every three months.

On Thursday, Alnylam reported that another of its RNAi drugs, cemdisiran, was ready to enter Phase III trials after announcing positive Phase II study results. The drug was co-developed with Regeneron Pharmaceuticals and is designed to treat patients with immunoglobulin A nephropathy (IgAN).

In the Phase II trial, there were 31 patients divided 2:1, placebo to cemdisiran. The patients receiving cemdisiran reported an average 37% decrease in urine protein to creatinine ratio, compared to placebo, recorded over a 24-hour period. The primary endpoint was a change from baseline of the 24-hour urine protein to creatinine ratio.

As BioSpace previously reported, the company announced its five-year strategy, “Alnylam P5x25,” at the 2022 J.P. Morgan Health Care Conference in January. This includes the development of several investigational drugs, including RNAi products for Alzheimer’s disease, Stargardt disease and gout.

At the time, Greenstreet said the company will serve “at least half a million patients around the world, as well as bring forward more marketed medicines – six plus – and continue to build this rich clinical pipeline.”

The Alzheimer’s product, ALN-APP, will begin a Phase I trial this year with data expected before 2023. The company’s gout therapeutic, ALN-XDH, is also expected to report Phase I data this year. Vutrisiran is being developed for several diseases, including hATTR and Stargardt disease, which is expected to start a Phase III trial later this year.

“The FDA approval of Amvuttra is very encouraging for the hATTR amyloidosis community, who need additional therapies to address the polyneuropathy of this progressive, life-threatening, multisystem disease,” Dr. Michael Polydefkis, M.D., MHS, professor, Johns Hopkins Neurology and HELIOS-A study investigator, said in a statement. “Amvuttra is a new therapeutic option that has demonstrated the potential to halt or reverse polyneuropathy progression in patients with an acceptable safety profile, along with an infrequent, subcutaneous dosing regimen that may also help to improve the disease management experience for patients.”

Source: BioSpace

June 14, 2022/by BioSpace
Tags: Alnylam Pharmaceuticals, Amvuttra, hereditary transthyretin-mediated amyloidosis (hATTR), immunoglobulin A nephropathy (IgAN), polyneuropathy, rare disease, rare genetic diseases, Regeneron Pharmaceuticals, RNA interference (RNAi) therapeutic, U.S. Food and Drug Administration (FDA)
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail
https://www.pharmalive.com/wp-content/uploads/2022/06/BioSpaceAlnylamCEO6-14-2022.jpg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-06-14 11:42:542022-06-14 12:06:21Alnylam scores another FDA nod in hATTR
You might also like
Merck wins key FDA approval for pediatric pneumococcal vaccine
Julia Weiss, Ogilvy Health Small town, big impact: Smart storytelling in rare disease
Baby formula shortage could ease as Abbott reopens Michigan plant
U.S. FDA staff says Moderna COVID vaccine effective and safe for children
AstraZeneca, Ionis eye U.S. approval after positive trial data
U.S. FDA advisers overwhelmingly back Moderna COVID vaccine for ages 6-17
Disappointing results end 9 Meters' Phase III trial for celiac treatment
AstraZeneca rumored to have set sights on Mereo BioPharma buyout
Recent
  • FDA pushes back review period for Provention Bio’s...July 1, 2022 - 11:07 am
  • U.S. orders 2.5 million more doses of Bavarian Nordic’s...July 1, 2022 - 11:01 am
  • Continuing transformation, Bayer opens Genetown research...July 1, 2022 - 10:59 am
  • FDA reportedly OKs future trial for pig-to-human organ ...July 1, 2022 - 10:41 am
Popular
  • FDA pushes back review period for Provention Bio’s...July 1, 2022 - 11:07 am
  • M&A, Partnerships And CollaborationsJanuary 1, 2011 - 1:48 pm
  • OTC Review And OutlookMarch 9, 2011 - 4:17 pm
  • Global Contract Manufacturing Companies: Pharmaceutical...November 11, 2011 - 3:31 pm
Tags
Abbott AstraZeneca BioNTech Bristol-Myers Squibb Business cancer clinical trials Coronavirus Disease (COVID-19) Pandemic Covid-19 COVID-19 pandemic COVID-19 vaccines Data FDA FDA/Regulatory FDA approval featured healthcare advertising agencies healthcare communications Healthcare Communications Agencies Johnson & Johnson Manufacturing Moderna monkeypox mRNA-1273/Moderna COVID-19 Vaccine Novartis Omicron subvariants Omicron variant Oncology Outbreaks pediatric vaccines people on the move Pfizer Public health public health authorities public health emergencies R&D rare disease Roche Sanofi U.S. Food and Drug Administration (FDA) United States Vaccines WHO World Health Organization zoonotic diseases
© Copyright - PharmaLive and Outcomes LLC | Designed by Joe Lumi LLC
  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
WPP appoints Michael Houston as President of its U.S. business Michael Houston, WPP On a partnering spree, Evotec announces new Janssen alliance
Scroll to top
Posting....

X